Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus

Overexpression of decoy receptor (DcR) 3 protein, a recently discovered member of the tumor necrosis factor receptor superfamily, was examined in 40 esophagogastrectomy specimens containing areas of Barrett esophagus (n = 27), low-grade dysplasia (n = 27), high-grade dysplasia or carcinoma in situ (n = 22), and esophageal adenocarcinoma (EAC; n = 28) with immunohistochemical analysis. The results revealed significantly more overexpression of DcR3 in high-grade dysplasia or carcinoma in situ and EAC than in benign esophageal mucosa (both P < .0001), Barrett esophagus (both P < .001), and low-grade dysplasia (P < .01 and P = .033, respectively). Low-grade dysplasia also showed significant overexpression of DcR3 compared with benign esophagus (P < .05) but not with Barrett esophagus (P > .05). DcR3 overexpression seems to negatively correlate with the grade of EAC. Our results suggest that overexpression of DcR3 protein might aid in the diagnosis of high-grade dysplasia or carcinoma in situ and EAC and also might serve as a potential therapeutic target.     

乌拉地尔缓释胶囊相对生物利用度和体内外相关性研究

 目的　对乌拉地尔缓释胶囊进行相对生物利用度和体内外相关性研究。方法　采用反相高效液相色谱法测定24名健康志愿受试者单剂量和多剂量口服乌拉地尔缓释胶囊供试制剂与参比制剂后乌拉地尔血药浓度的变化。用3P97药动学程序处理试验数据,并对试验结果进行方差分析和双单侧t检验;体外释放度采用中国药典2000版二部的转篮法。结果 单剂量试验乌拉地尔的相对生物利用度为:(96.37±13.77)%;两种制剂乌拉地尔的药-时曲线下面积(AUC_0→t)分别为:(2347.6±493.2),(2458.9±526.5 )ng·h·mL^-1;达峰时间(t_max)分别为:(4.17±0.28),(4.23±0.29)h;峰浓度(c_max)分别为:(325.6±40.3),(322.0±75.5 )ng·mL^-1。多剂量试验乌拉地尔的相对生物利用度为:(99.99±16.24)%;两种制剂乌拉地尔的药-时曲线下面积(AUC_0→t)分别为:(4513.1±1372.7) ,(4549.7±1308.8)ng·h·mL^-1;稳态达峰时间(t_max)分别为:(4.00± 0.49),(4.08±0.43)h;稳态峰浓度(c_max)分别是 :(544.5±147.1),(565.7±146.8)ng·mL^-1;波动度DF分别是(91.22±14.07)%,(84.53±26.10)%。体外12h平均累积释放86.33%和87.35%。结论　对单剂量口服两种制剂后的lnAUC_0→∞,lnAUC_0→t,lnc_max经双单侧t检验，t_max经秩和检验进行生物等效性评价，表明两者为生物等效制剂，且乌拉地尔缓释胶囊的体内吸收与体外释药有良好的相关性(P<0.05)。     

Triterpenes from Astilbe chinensis

Six new triterpenes, 3β,6β-dihydroxyurs-12-en-27-oic acid (1), 3β,6β,24-trihydroxyurs-12-en-27-oic acid (2), 3β,6β,7α-trihydroxyurs-12-en-27-oic acid (3), 3β-acetoxy-6β-hydroxyurs-12-en-27-oic acid (4), 3β,6β,24-trihydroxyolean-12-en-27-oic acid (5), and 3β,6β,7α-trihydroxyolean-12-en-27-oic acid (6), were isolated from the rhizomes of Astilbe chinensis. Their structures were elucidated on the basis of 1D- and 2D-NMR analyses and HR-MS experiments. The isolated compounds exhibited significant cytotoxic activities against the SK-N-SH and HL-60 cell lines.     

凝胶迁移阻滞法分析人类端粒酶的DNA结合特性

目的 采用凝胶迁移阻滞法分析研究人类端粒酶DNA结合特性。方法 以地高辛标记的人端粒序列寡核苷酸与人端粒酶提取物进行结合反应，以未参与结合反应的单纯标记寡核苷酸作为参照。实验所设的3组样品中，第一组和第二组标记寡核苷酸加端粒酶，第一组显示一条阻滞性条带，第二组显示两条条带，前方的一条与第一组条带平行，为单纯探针条带，后方的一条迁移率被阻滞，应为探针与纯化的蛋白复合体相结合的结果；第三组为标记寡核苷酸加端粒酶阴性洗涤液，只显示单一探针条带。结果 只有人端粒序列寡核苷酸与人端粒酶提取物结合反应管显示特异的凝胶迁移阻滞性电泳条带。结论 人端粒酶具有和端粒DNA片段结合的特性。     

Up-regulation of microRNA-155 promotes cancer cell invasion and predicts poor survival of hepatocellular carcinoma following liver transplantation

Purpose  

MicroRNAs play important roles in cancer development, progression, and metastasis. The aim of this study was to determine whether altered microRNA-155 expression is associated with hepatocellular carcinoma (HCC) recurrence and prognosis following orthotopic liver transplantation (OLT).     

Biodegradable Drug-Eluting Poly[lactic-co-glycol acid] Nanofibers for the Sustainable Delivery of Vancomycin to Brain Tissue: In Vitro and in Vivo Studies

相似文献   

选择性合成2-硫嘧啶烷基取代产物（英文）

目的研究2-硫嘧啶S上烷基取代反应。方法以2-硫嘧啶为原料,分别采用K2CO3方法和CH3ONa-CH3OH方法,合成了2位硫烷基取代产物。采用1^H NMR,IR,质谱鉴定了产物。结果高度区域选择性地、以较好的收率得到了2位硫烷基取代产物。结论CH3ONa-CH3OH方法可以高度区域选择性地合成2位硫烷基取代产物,而K2CO3方法得到多取代烷基化产物。     

1-烷基-5-氨基-6-苯乙基尿嘧啶的合成

研究1-烷基-5-氨基-6-苯乙基尿嘧啶（1a，1b）方便、高产率的合成方法，此类化合物有可能作为非核苷类HIV-1RT抑制剂。以6-甲基尿嘧啶（2）为起始物，经硝化、烷基化、苄基化及一锅反应脱苄基及还原反应等合成目标化合物，并用NMR、MS、IR、Anal鉴定化合物结构。探索出了一种合成1-烷基-5氨基-6-苯乙基尿嘧啶类化合物的方便方法。首次于用3或4步反应、高产率合成了1-烷基-5-氨基-6-苯乙基尿嘧啶（1a，1b）并发现化合物1a有中度抗HIV-1RT的活性（IC50=29μM）。